HIV coinfection with tuberculosis prevention
|
HIV coinfection with tuberculosis Microchapters |
|
Differentiating HIV coinfection with tuberculosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV coinfection with tuberculosis prevention On the Web |
|
American Roentgen Ray Society Images of HIV coinfection with tuberculosis prevention |
|
Directions to Hospitals Treating HIV coinfection with tuberculosis |
|
Risk calculators and risk factors for HIV coinfection with tuberculosis prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
A new epidemiological model, developed by WHO, UNAIDS and the Stop TB Partnership, shows it is possible to reduce HIV/AIDS deaths impressively through tuberculosis (TB) prevention and treatment. In 2009 almost one in four deaths among people living with HIV were due to TB, a disease that is both curable and preventable. The model estimates that through the scaled-up implementation of WHO-recommended collaborative TB/HIV activities, it is possible to save a million lives by the end of 2015. Symptom Screening, measurement of CRP and chest radiography are used as a screening modality. A parallel strategy of symptom screening and chest radiography has higher sensitivity.
Prevention
A publication 'Time to act: Save a million lives by 2015 – Prevent and treat tuberculosis among people living with HIV' was launched on June 6, 2011 at the UN headquarters in New York. It calls for the following actions:
- Testing for HIV and TB should be provided every three years in places where both diseases are prevalent.
- Prompt TB treatment needs to be provided to every person living with HIV with active TB - or else treatment to prevent TB.
- HIV and TB treatment must be accessible and of good quality so that people living with HIV are cured of TB.
- Antiretroviral therapy (ART) should be started early, which will help prevent TB, since people living with HIV are far less likely to become ill with and die of TB if they begin ART before their immune systems begin serious decline.
- People who are HIV-positive and diagnosed with active TB should start ART regardless of the status of their immune systems.
- There is a strong evidence base showing that many different regimens of preventive therapy reduce incident tuberculosis among people with HIV infection, including those receiving ART.
- Shorter rifamycin-based regimens were associated with a lower risk of hepatotoxic effects and a lower risk of death and were more likely to be completed than isoniazid-based regimens.
Vaccinations
- The BCG vaccine is partially protective against severe forms of tuberculosis in children but has no clear benefit in adults.
- The M72/AS01E vaccine(composed of a fusion protein of two M. tuberculosis antigens with a potent adjuvant.) a vaccine in trial phase 2 is shown to reduced the incidence of tuberculosis by 50% among adults without HIV infection. In phase 3 which began in 2024 ,people with HIOV are included to study its effects.